The Vasculitis Clinical Research Consortium (VCRC) was established in 2003 and in 5 years of rapid growth and productivity has become the major clinical research infrastructure in North America dedicated to the study of vasculitis. The VCRC is a founding member and leading force of the NIH Rare Diseases Clinical Research Network (RDCRN). By conducting a series of longitudinal cohort studies, biomarker discovery projects, multicenter clinical trials, and outcome measure development projects, the Consortium is addressing serious unmet medical and scientific needs for this group complex rare diseases. The VCRC currently has over 500 patients in clinical research on the following 6 types vasculitis: giant cell arteritis. Takayasu's arteritis, polyarteritis nodosa, Wegener's granulomatosis, microscopic polyangiitis, and Churg-Straus Syndrome. Each of these diseases are consider """"""""orphan"""""""" diseases. Additionally, partnership with patient advocacy groups has been a critical component to the success of t he VCRC. The VCRC electronic resources are important for patients worldwide. The VCRC Fellowship Program has successfully trained new clinical investigators, each of whom remains engaged in academic research in vasculitis. This proposal outlines a total of 13 separate clinical protocols with 10 associated studies of biomarkers . VCRC investigators have successfully obtained ancillary funding to allow for expansion of the Consortium's work. Sources of these funds include the NIH, the FDA, private foundations and the biopharmaceutical industry. This application seeks refunding of the VCRC to both support the critical administrative , laboratory, biostatistical cores and allow completion of ongoing projects, launch of exciting new scientific initiatives training of new investigators in clinical research in vasculitis, and expansion of the VCRC website.
The Vasculitis Clinical Research Consortium (VCRC) combines the clinical and scientific expertise of several major academic medical centers in North America to conduct a series of research projects in several types of vasculitis. Vasculitis is a serious but rare set of diseases and the combined efforts of the VCRC investigators will seek to address important unanswered questions about the causes and best treatments for vasculitis. The VCRC will also teach other physicians about vasculitis and will work closely with vasculitis patient advocacy groups.
Kermani, Tanaz A; Sreih, Antoine G; Cuthbertson, David et al. (2018) Evaluation of damage in giant cell arteritis. Rheumatology (Oxford) 57:322-328 |
Springer, Jason Michael; Monach, Paul; Cuthbertson, David et al. (2018) Serum S100 Proteins as a Marker of Disease Activity in Large Vessel Vasculitis. J Clin Rheumatol 24:393-395 |
Robson, Joanna C; Dawson, Jill; Cronholm, Peter F et al. (2018) Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. Patient Relat Outcome Meas 9:17-34 |
Grayson, Peter C; Eddy, Sean; Taroni, Jaclyn N et al. (2018) Metabolic pathways and immunometabolism in rare kidney diseases. Ann Rheum Dis 77:1226-1233 |
Barra, Lillian; Borchin, Renée L; Burroughs, Cristina et al. (2018) Impact of vasculitis on employment and income. Clin Exp Rheumatol 36 Suppl 111:58-64 |
Robson, Joanna C; Dawson, Jill; Doll, Helen et al. (2018) Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann Rheum Dis 77:1157-1164 |
Sreih, Antoine G; Alibaz-Oner, Fatma; Easley, Ebony et al. (2018) Health-related outcomes of importance to patients with Takayasu's arteritis. Clin Exp Rheumatol 36 Suppl 111:51-57 |
Sreih, Antoine G; Ezzedine, Rana; Leng, Lin et al. (2018) Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. Arthritis Rheumatol 70:2077-2086 |
Kermani, Tanaz A; Diab, Sehriban; Sreih, Antoine G et al. (2018) Arterial lesions in giant cell arteritis: A longitudinal study. Semin Arthritis Rheum : |
Quinn, Kaitlin A; Ahlman, Mark A; Malayeri, Ashkan A et al. (2018) Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis 77:1165-1171 |
Showing the most recent 10 out of 88 publications